Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

+ Free Shipping
Guaranteed Safe Checkout

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action.[1] Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[2][3][4][5] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[6] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.[1]

Interactions

Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)-

Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- Struktur
1391487-26-5
CAS-Nr.
1391487-26-5
Englisch Name:
Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)-
Synonyma:
Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)-
CBNumber:
CB110028338
Summenformel:
C16H25N3O3
Molgewicht:
307.39
MOL-Datei:
1391487-26-5.mol
Request For Quotation

Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- Eigenschaften

Siedepunkt:
543.5±50.0 °C(Predicted)
Dichte
1.168±0.06 g/cm3(Predicted)
pka
14.92±0.46(Predicted)
CAS No.1391487-26-5] A981724 Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- 97%
Catalog No. 
Cas No.: 
Molecular Formula: 
Molecular Weight: 
*All chemicals from our company are for laboratory and manufacturing use only.
Quality Control of [1391487-26-5]

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5

Product Details [1391487-26-5]
Synonyms:
Appearance:
Melting point:
Boiling point: 
Flash point:
Storage: 
Pubchem ID:
Smiles: 
Inchi: 
InchiKey: 
Safety [1391487-26-5]
Pictogram:
Signal word:
UN No.:
Danger Category:
Packing Group:
Hazard statements:
Precautionary statements:
Literatures [1391487-26-5]
Sorry, the literature is not available.
Similar of [1391487-26-5]
Description [1391487-26-5]

Buy Lys-MDA Cas 1391487-26-5

Buy Lys-MDA Cas 1391487-26-5

Buy Lys-MDA Cas 1391487-26-5

Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action.[1] Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[2][3][4][5] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[6] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.[1]

Interactions

Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- Chemische Eigenschaften,Einsatz,Produktion Methoden

Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

  1. Buy Lys-MDA Cas 1391487-26-5 – Cas 1391487-26-5 Buy

    Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment …

  2. Lys-MDA | C16H25N3O3 | CID 177841565 – PubChem

     Lys-MDA | C16H25N3O3 | CID 177841565 – structure, chemical names, physical and chemical properties, …

  3. Hexanamide, 2,6-diamino-N- [2- (1,3-benzodioxol-5-yl)-1-methylethyl …

    Hexanamide, 2,6-diamino-N- [2- (1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)-,,1391487-26-5,,C16H25N3O3

  4. Lys-MDA – Wikipedia

    Lys-MDA – Wikipedia. Jump to content. Main menu. move to sidebarhide. Navigation . Main page. Contents. Current events. …

  5. Hexanamide, 2,6-diamino-N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl …

    Hexanamide, 2,6-diamino-N- [2- (1,3-benzodioxol-5-yl)-1-methylethyl]-, (2S)- (CAS 1391487-26-5) information, including chemical …

  6. N-(L-Lysinamidyl)-3,4-methylenedioxyamphetamine – Wikipedia

    In other projects Appearance move to sidebar hide Lys-MDA

  7. Chemistry:Lys-MDA – HandWiki

     Lys-MDA (Lysine-MDA, N- (L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative …

  8. Hexanamide, 2,6-diamino-N- [2- (1,3-benzodioxol-5-yl)-1-methylethyl …

    You can also browse global suppliers,vendor,prices,Price,manufacturers of Hexanamide, 2,6-diamino-N- [2- (1,3-benzodioxol-5-yl)-1 …

  9. Lys-MDA – Wikiwand

     Lys-MDA (Lysine-MDA, N- (L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative …

  10. Lys-MDA – Wikiwand

    Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment …

Reviews

There are no reviews yet.

Be the first to review “Buy Lys-MDA (N-(L-lysinamidyl) Cas 1391487-26-5”

Your email address will not be published. Required fields are marked *

Shopping Cart